Based on the key indicators related to Protagenic Therapeutics' liquidity, profitability, solvency, and operating efficiency, Protagenic Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Protagenic Therapeutics' Other Assets are fairly stable compared to the past year. Capital Stock is likely to climb to 758.80 in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 294.3 K in 2025. Key indicators impacting Protagenic Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Protagenic Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Protagenic Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Protagenic Therapeutics.
Please note, the imprecision that can be found in Protagenic Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protagenic Therapeutics. Check Protagenic Therapeutics' Beneish M Score to see the likelihood of Protagenic Therapeutics' management manipulating its earnings.
Protagenic Therapeutics Stock Summary
Protagenic Therapeutics competes with Inspira Technologies. Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company was founded in 2016 and is based in New York, New York. Protagenic Therapeutics is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Protagenic Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Protagenic Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Protagenic Therapeutics's current stock value. Our valuation model uses many indicators to compare Protagenic Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Protagenic Therapeutics competition to find correlations between indicators driving Protagenic Therapeutics's intrinsic value. More Info.
Protagenic Therapeutics is regarded second in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . At this time, Protagenic Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Protagenic Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Protagenic Therapeutics Market Pulse
Quote
0.0034
Change(%)
0.00
Change
0.00
Open
0.0034
Low
0.0032
High
0.0034
Volume
0
Exchange
NASDAQ
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Protagenic Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Protagenic has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Protagenic Therapeutics' financials are consistent with your investment objective using the following steps:
Review Protagenic Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
Study the cash flow inflows and outflows to understand Protagenic Therapeutics' liquidity and solvency.
Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
Compare Protagenic Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Protagenic Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.
Today, most investors in Protagenic Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Protagenic Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Protagenic Therapeutics growth as a starting point in their analysis.
Protagenic Therapeutics March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Protagenic Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Protagenic Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Protagenic Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Protagenic Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Protagenic Therapeutics's daily price indicators and compare them against related drivers.
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.